Molina Healthcare Inc (MOH)
Official siteHEALTHCARE • HEALTHCARE PLANS • NYSE
Market Cap: $10.89B
Last updated: Nov 17, 2026 at 11:06 AM ET
Molina Healthcare Inc (MOH) Stock Forecast
Analysts expect Molina Healthcare (MOH) to earn $5.27 per share in the fiscal year ending Dec 31, 2026, on revenue of $44.74B. Of 19 analysts, 4 rate the stock Buy or Strong Buy, 14 Hold and 1 Sell or Strong Sell, for a consensus of Hold. Over the last 30 days, 9 estimates for the fiscal year ending Dec 31, 2026 were revised up and 4 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 19 ratings average 2.84, inside the Hold band from 2.5 up to 3.5. Buy and Strong Buy make up 21% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 1 | 5.3% |
| Buy | 3 | 15.8% |
| Hold | 14 | 73.7% |
| Sell | 0 | 0.0% |
| Strong Sell | 1 | 5.3% |
- Consensus
- Hold
- Total analysts
- 19
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus rises 81.0% and revenue estimates rise 6.5%.
- Fiscal year ending Dec 31, 2026
- $5.27
- EPS consensus, revenue $44.74B
- Fiscal year ending Dec 31, 2027
- $9.54
- EPS consensus, revenue $47.63B
- Next report
- Feb 3, 2027
- Estimated
EPS range
Revenue range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | $5.27 | $5.19 to $5.58 | 19 | $44.74B | $43.98B to $45.30B | 16 |
| Dec 31, 2027 | $9.54 | $8.88 to $10.17 | 6 | $47.63B | $46.20B to $48.75B | 15 |
Quarterly Estimates
The EPS consensus rises from $0.54 for the quarter ending Dec 31, 2026 to $3.01 for the quarter ending Mar 31, 2027.
EPS range
Revenue range
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | $0.54 | $0.44 to $0.77 | 21 | $12.01B | $10.42B to $13.18B | 17 |
| Mar 31, 2027 | $3.01 | $2.07 to $3.81 | 13 | $11.76B | $10.88B to $12.09B | 8 |
Estimate Revisions
Across the 3 periods below, the last 30 days brought 19 upward and 10 downward EPS revisions.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 9 | 4 |
| Fiscal year ending Dec 31, 2027 | 2 | 3 |
| Quarter ending Mar 31, 2027 | 8 | 3 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has risen 0.6% from $5.24.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | $5.27 | $5.27 | $5.25 | $5.24 | $5.24 | +0.6% |
| Fiscal year ending Dec 31, 2027 | $9.54 | $9.54 | $8.55 | $8.55 | $8.55 | +11.5% |
| Quarter ending Mar 31, 2027 | $3.01 | $3.07 | $3.07 | $3.06 | $3.05 | -1.2% |
Frequently Asked Questions About MOH
What is the MOH stock forecast?
Consensus analyst estimates put Molina Healthcare's EPS at $5.27 for the fiscal year ending Dec 31, 2026, on revenue of $44.74B. The consensus rating from 19 analysts is Hold.
How do analysts rate MOH stock?
Of 19 analysts covering Molina Healthcare, 1 rates it Strong Buy, 3 Buy, 14 Hold, 0 Sell and 1 Strong Sell, for a consensus of Hold.
What EPS do analysts expect from MOH next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is $5.27, with estimates from $5.19 to $5.58 from 19 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is $9.54, with estimates from $8.88 to $10.17 from 6 analysts.
What revenue do analysts expect from Molina Healthcare next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $44.74B, with estimates from $43.98B to $45.30B. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $47.63B, with estimates from $46.20B to $48.75B.
How many analysts cover MOH?
19 analysts rate Molina Healthcare stock, and 19 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
MOH pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors